Добавил:

Sekretar kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.

Вуз:

Ростовский Государственный Медицинский Университет

Предмет:

Медицина общая

Файл:

Книга_5698_Библиотеки_им_академика_М_И_Перельмана

.pdf

Скачиваний:

Добавлен:

12.10.2026

Размер:

7 Мб

Скачать

☆

<<< < Предыдущая 17 18 19 20 21 22 23 24 25 26 27 2829 / 4929 30 31 32 33 34 35 36 37 38 39 40 41 > Следующая >>>

TABLE 10.2 Enzymes involved in metabolism of herbal drugs and their mechanism of interaction.

Sr.

No. Enzyme Drug Effect Reference

1. CYP3A,

CYP3A4 and P-gp

Ginkgo

biloba

Inhibit CYP3A by both intestinal and hepatic metabolism

and increases bioavailability of diltiazem. Tolbutamide and

midazolam’s pharmacokinetics and pharmacodynamics are

inﬂuenced by CYP3A4 and P-gp.

[32,33]

2. CYP3A4 and P-gp St. John’s

Wort (SJW)

(Hypericum

perforatum)

Interact with HIV protease inhibitor drugs such as irinotecan,

benzodiazepines like alprazolam, theophylline, verapamil,

and warfarin. Also reduce the plasma level of cyclosporine,

leading to rejection of a transplanted organ.

[34,35]

3. CYP1A2 e CYP1A subfamily enzyme CYP1A2 is expressed exclusively

in the liver, and with a low extent in the intestines and lungs.

CYP1A is responsible for the activation of carcinogens.

[31,36]

4. CYP2C9 e Expressed in the liver and less expression in the intestine and

kidneys. Responsible for the catabolism of several drugs,

such as tolbutamide and S-warfarin.

[30,37]

5. CYP2D6 e Expressed mainly in the liver, including intestines and brain,

and metabolizes a wide variety of drugs like

dextromethorphan and debrisoquine.

[38]

6. Uridine diphosphate

glucuronosyltransferase

(UGT)

e Responsible for the metabolism of almost all drugs including

xenobiotics, dietary phytochemicals, etc.

[39]

Lack of adequate

knowledge about herb

drug interaction

No quality control and

assurance for the purity

and safety

No advance research on

herb drug interaction

Avoidance of patient

history about drug

sensitivity

Adulteration in herbal

drugs

Some reasons of herb

drug interaction

FIGURE 10.2 Reasons of herb-drug interactions.

10. Herbal drug interaction and effects on phytopharmaceuticals258

https://t.me/med1917

physiological climate. The primary fundamental mechanism of pharmacokinet ic herb-drug

interactions is the ability of digestive and hepatic metabolic catalysts, particularly the CYP

protein family, to be either accepted or inhibited. In most circumstances, it is also important

to consider the relative inﬂuence on drug carriers and efﬂux proteins, particularly the p-

glycoproteins in the digestive tracts [40]. The balancing movement of codirected herbal

products has been shown to cause a clear fall or increase in the blood levels of the affected

drugs because the prefoundational activity of CYP and efﬂux protein mildly affect oral

bioavailability. From in vitro studies with liver chemicals, it is frequently concluded that

there is potential for drug partnerships in vivo. Even though it is difﬁcult to determine

the degree of clinical signiﬁcance, the relationship between in vitro results and in vivo

behavior has occasionally produced reliable results with regard to in vivo consistency. As

aresult,thevastmajorityofthedocumentedherb-drug interactions were initially demon-

strated through in vitro studies, as will be seen in the next segments [33]. Additionally,

herbal products’ interactions with hepatic molecules may have pharmacodynamic effects

[8].The height for transaminases, severe and continuous hepatitis, liver disappointment,

veno-occlusive problems, liver cirrhosis, ﬁbrosis, cholestasis, zonalor diffusive h epatic pu-

trefaction, and steatosis are all symptoms of explicit liver injury caused by phytochemical

experts. Oxidative stress, mitochondrial damage, apoptosis, and bioactivation of CYP are

possible causes of liver damage [41,42].

9. Examples of herb-drug interaction

Herb-drug interaction has turned into a major issue since natural medication is broadly

utilized in the cutting e dge world and is liked to be e liminated from the body by the very

system that eliminates drugs. This creates the potential for interaction between herbs and

medications. A portion of the natural medications with their mechanism of interaction

and mixtures with which these medications show collaboration are accumulated in

Table 10.3.

10. Conclusion

Herb-drug interactions are a signiﬁcant issue for the clinical remedial viability of medica-

tion treatment. They inﬂuence either the pharmacokinetic properties or pharmacodynamics

exercises of medications, prompting disappointment or toxic levels. For some normally uti-

lized therapeutic herbs, their pharmacokinetic collaborations for certain normally utilized al-

lopathic medications have been broadly studied. The signiﬁcant instruments liable for a large

portion of pharmacokinetic collaborations are the balance of digestion catalysts exercises

especially the CYP isozymes and the layer carriers exercises especially the efﬂux carrier P-

gp. In correlation with the investigations in pharmacokinetics, herb-drug collaborations in

pharmacodynamics are undeniably less contemplated. More considerations and endeavors

ought to be put into this space. These interactions are muddled, and the clinical results might

be an outcome of the connections in both pharmacokinetics and pharmacodynamics. The

absence of information on the potentially dangerous herb-drug collaborations will put a

10 Conclusion 259

https://t.me/med1917

TABLE 10.3 Some herbal drugs and their mechanism of interaction.

Sr.

No. Herbal drug Interacting drug Mechanism of interaction References

1. Cranberry (fruit

extract)

CYP1A2, 2C9, 3A4 substrates and

warfarin

P-gp and CYP enzyme inhibition [43]

2. Garlic (bulb) CYP2D6, 3A4 substrates, warfarin and

saquinavir

CYP 3A4 and P-gp induction [43,44]

3. Ginseng (root) Imatinib, CYP2E1, and 2D6 substrates Inhibition and induction of CYP2C9,

2C19, 2D6, and 3A4 activity

[45e48]

4. Liquorice (root) CYP2B6, 2C9, and 3A4 substrates Inhibition of CYP2B6, 2C9, and 3A4 [49]

5. St John’s wort

(aerial parts)

Orally administered CYP substrates Inhibition and induction of CYP and P-gp [34,50]

6. Cascara

(Rhamnus

purshiana)

Orally administered drugs Increasing GIT motility [7,51]

7. Ginger(Zingiber

ofﬁcinale)

Diclofenac, anticoagulants Antiemetic, antiplatelet, antiulcer [52,53]

8. Styrax extract Warfarin Inhibited human CYP3A and mildly

inhibited six other human CYPs that were

examined

[54]

9. Rhubarb

(Rheum

ofﬁcinale)

e Applied as a laxative renal disease such as

renal stone production may be accelerated

by high oxalic acid concentration

[55,56]

10. Dong quai

(root) (Angelica

sinensis)

CYP substrates Inhibition of CYP1A2, 3A4, and P-gp [43,57]

11. Aloe vera Cardiac glycosides, thiazide diuretics Can result in hypokalemia and electrolyte

imbalance; may increase medication

toxicity

[9,43]

12. Turmeric

(Curcuma longa)

Antiplatelet agents Herb includes curcumin, which could

enhance its antiplatelet effects

[58e61]

13. Senna (Cassia

acutifolia)

Digitalis, diuretics Drug toxicity may increase with

prolonged usage and result in

hypokalemia

[62,63]

14. Karela (bitter

gourd)

Hypoglycemic drugs Potentiates drug effect [64,65]

15. Ma-huang

Ephedra

Oxytocin, methyldopa, b-blockers,

caffeine, monoamine oxidase inhibitors,

theophylline, sympathomimetics, St.

John’s wort, guanethidine, cardiac

glycosides

Enhanced sympathomimetic activity;

could cause hypertension; could stimulate

the CNS

[66,67]

10. Herbal drug interaction and effects on phytopharmaceuticals260

https://t.me/med1917

huge danger to patients’ wellbeing in clinical beneﬁts. In actuality, a few collaborations might

be remedially advantageous. It could be utilized to assist with growing new remedial proced-

ures later on. Herb-drug collaborations have been progressively announce d, yet are underin-

vestigated. By and large, there is no conceivable system to clarify the noticed peculiarities and

causality is unsure. To precisely analyze, treat, and screen a patient’s thorough arrangement

of care, medical services experts should incorporate evaluation of herbal medication use. A

deﬁnitive objective of this article is to raise the mindfulness of drug specialists and doctors

in regard to this point furthermore, consequently safeguard the wellbeing of buyers. Logical

proposals on the utilization of herbs and their coadministration with regular treatment ought

to be founded on strong logical information rather than on the deﬁcient information of case

reports as it were. Forthcoming randomized clinical preliminaries evaluating herbal-drug

interaction is a critical need.

Conﬂict of interest

The authors declare no conﬂict of interest, ﬁnancial or otherwise.

Acknowledgment

The authors acknowledge the Department of Science and Technology, New Delhi, India (DST/INSPIRE Fellowship/

2019/IF190329, DST/NM/NT/2018/20 and DST-FIST Letter no-SR/FST/COLLEGE/2018/418, New Delhi) for

providing ﬁnancial assistance for the successful completion of this work.

References

[1] Singh A, Zhao K. Herbedrug interactions of commonly used Chinese medicinal herbs. 1st ed.vol 135. Elsevier

Inc.; 2017. https://doi.org/10.1016/bs.irn.2017.02.010.

[2] Balap A, Atre B, Lohidasan S, Sinnathambi A, Mahadik K. Pharmacokinetic and pharmacodynamic herb-drug

interaction of Andrographis paniculata (Nees) extract and andrographolide with etoricoxib after oral adminis-

tration in rats. Journal of Ethnopharmacology 2016;183:9e17. https://doi.org/10.1016/j.jep.2015.11.011.

[3] Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Medical Principles

and Practice 2012;21:404e28. https://doi.org/10.1159/000334488.

[4] Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. British Journal of

Clinical Pharmacology 2001;52(5):587e95.

[5] Alissa EM. Medicinal herbs and therapeutic drugs interactions. Therapeutic Drug Monitoring 2014;36:413e22.

https://doi.org/10.1097/FTD.0000000000000035.

[6] Liu MZ, Zhang YL, Zeng MZ, He FZ, Luo ZY, Luo JQ, et al. Pharmacogenomics and herb-drug interactions:

merge of future and tradition. Evidence-Based Complementary and Alternative Medicine 2015;2015. https://

doi.org/10.1155/2015/321091.

[7] Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herbedrug interaction studies with special

focus on interplays: a prerequisite for integrative medicine. Porto Biomedical Journal 2019;4:e15. https://

doi.org/10.1016/j.pbj.0000000000000015.

[8] Van Den Bout-Van Den Beukel C, Koopmans P, Van Der Ven A, De Smet P, Burger D. Possible drug-metabolism

interactions of medicinal herbs with antiretroviral agents. Drug metabolism reviews 2006;38:477e514. https://

doi.org/10.1080/03602530600754065.

[9] Kahraman C, Ceren Arituluk Z, Irem Tatli Cankaya I. The clinical importance of herb-drug interactions and toxi-

cological risks of plants and herbal products. Medical Toxicology 2021. https://doi.org/10.5772/

intechopen.92040.

References 261

https://t.me/med1917

[10] SGD O. The possibility of interactions between medicinal herbs and allopathic medicines used by patients

attended at basic care units of the Brazilian uniﬁed health system. Natural Products Chemistry & Research

2015;3. https://doi.org/10.4172/2329-6836.1000171.

[11] Tarirai C, Viljoen AM, Hamman JH. Herb – drug pharmacokinetic interactions reviewed. Expert Opinion on

Drug Metabolism & Toxicology 2010:1515e38.

[12] Pasi AK. Herb-drug interaction: an overview. International Journal of Pharmaceutical Sciences and Research

2013;4:3770e4. https://doi.org/10.13040/IJPSR.0975-8232.4(10).3770-74.

[13] Pandit S, Kanjilal S, Awasthi A, Chaudhary A, Banerjee D, Bhatt BN, et al. Evaluation of herb-drug interaction of

a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay. Jour-

nal of Ethnopharmacology 2017;197:165e72. https://doi.org/10.1016/j.jep.2016.07.061.

[14] Kaur G. Potential adverse interactions between allopathic drugs, herbals and dietary products: mechanisms of

action and clinical implications. Journal of Diabetes & Metabolic Disorders 2016;3:1e2. https://doi.org/

10.24966/dmd-201x/100009.

[15] Fasinu PS, Bouic PJ, Rosenkranz B. An overview of the evidence and mechanisms of herb-drug interactions.

Frontiers in Pharmacology 2012;3:1e19. https://doi.org/10.3389/fphar.2012.00069.

[16] Kesarwani K, Gupta R. Bioavailability enhancers of herbal origin: an overview. Asian Paciﬁc Journal of Tropical

Biomedicine 2013;3:253e66. https://doi.org/10.1016/S2221-1691(13)60060-X.

[17] Tian X, Xu Z, Li Z, Ma Y, Lian S, Guo X, et al. Pharmacokinetics of mangiferin and its metabolitednorathyriol,

Part 2: inﬂuence of UGT, CYP450, P-gp, and enterobacteria and the potential interaction in Rhizoma Anemar-

rhenae decoction with timosaponin B2 as the major contributor. BioFactors 2016;42:545e55. https://doi.org/

10.1002/biof.1290.

[18] Hou ML, Lu CM, Tsai TH. Effects of Jia-Wei-Xiao-Yao-San on the peripheral and lymphatic pharmacokinetics of

paclitaxel in rats. Evidence-Based Complementary and Alternative Medicine 2016;2016. https://doi.org/

10.1155/2016/5614747.

[19] Shao X, Ai N, Xu D, Fan X. Exploring the interaction between Salvia miltiorrhiza and human serum albumin:

insights from herb-drug interaction reports, computational analysis and experimental studies. Spectrochimica

Acta Part A Mol Biomol Spectrosc 2016;161:1e7. https://doi.org/10.1016/j.saa.2016.02.015.

[20] Saengtienchai A, Ikenaka Y, Bortey-Sam N, Jermnark U, Mizukawa H, Kawai YK, et al. The African hedgehog

(Atelerix albiventris): low phase I and phase II metabolism activities. Comparative Biochemistry and Physiology,

Part C: Toxicology & Pharmacology 2016;190:38e47. https://doi.org/10.1016/j.cbpc.2016.08.005.

[21] Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interaction

and their implication in clinical management. Journal of Research in Medical Sciences 2013;18:600e9.

[22] Choi JG, Eom SM, Kim J, Kim SH, Huh E, Kim H, et al. A comprehensive review of recent studies on herb-drug

interaction: a focus on pharmacodynamic interaction. Journal of Alternative & Complementary Medicine

2016;22:262e79. https://doi.org/10.1089/acm.2015.0235.

[23] Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evidence-Based Comple-

mentary and Alternative Medicine 2014;2014. https://doi.org/10.1155/2014/957362

[24] Ge B, Zhang Z, Zuo Z. Radix Puerariae lobatae (Gegen) suppresses the anticoagulation effect of warfarin: a phar-

macokinetic and pharmacodynamics study. Chinese Medicine 2016;11:1e17. https://doi.org/10.1186/s13020-

016-0078-9.

[25] Fong SYK, Wong YC, Xie C, Zuo Z. Herb-drug interactions between Scutellariae Radix and mefenamic acid:

simultaneous investigation of pharmacokinetics, anti-inﬂammatory effect and gastric damage in rats. Journal

of Ethnopharmacology 2015;170:106e16. https://doi.org/10.1016/j.jep.2015.04.036.

[26] Katyal J, Sarangal V, Gupta YK. Interaction of hydroalcoholic extract of Acorus calamus Linn. with sodium val-

proate and carbamazepine. Indian Journal of Experimental Biology 2012;50:51e5.

[27] Bhadra R, Ravakhah K, Ghosh RK. Herb-drug interaction: the importance of communicating with primary care

physicians. Australasian Medical Journal 2015;8:315e9. https://doi.org/10.4066/AMJ.2015.2479.

[28] Mazhar H, Foster BC, Necyk C, Gardiner PM, Harris CS, Robaey P. Natural health product-drug interaction cau-

sality assessment in pediatric adverse event reports associated with attention-deﬁcit/hyperactivity disorder

medication. Journal of Child and Adolescent Psychopharmacology 2020;30:38e47. https://doi.org/10.1089/

cap.2019.0102.

[29] Shaikh AS, Thomas AB, Chitlange SS. Herbedrug interaction studies of herbs used in treatment of cardiovas-

cular disordersda narrative review of preclinical and clinical studies. Phytotherapy Research

2020;34:1008e26. https://doi.org/10.1002/ptr.6585.

10. Herbal drug interaction and effects on phytopharmaceuticals262

https://t.me/med1917

[30] Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for

improved predictions. Drug Metabolism & Disposition 2014;42:301e17. https://doi.org/10.1124/

dmd.113.055236.

[31] Na DH, Ji HY, Park EJ, Kim MS, Liu KH, Lee HS. Evaluation of metabolism-mediated herb-drug interactions.

Archives of Pharmacal Research 2011;34:1829e42. https://doi.org/10.1007/s12272-011-1105-0.

[32] Showande SJ, Fakeye TO, Kajula M, Hokkanen J, Tolonen A. Potential inhibition of major human cytochrome

P450 isoenzymes by selected tropical medicinal herbsdimplication for herbedrug interactions. Food Sciences

and Nutrition 2019;7:44e55. https://doi.org/10.1002/fsn3.789.

[33] Wanwimolruk S, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions (part 1).

EXCLI Journal 2014;13:347e91. https://doi.org/10.17877/DE290R-15628.

[34] Zhou S-F, Lai X. An update on clinical drug interactions with the herbal antidepressant St. Johns wort. Current

Drug Metabolism 2008;9:394e409. https://doi.org/10.2174/138920008784746391.

[35] Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Phar-

macological Research 2010;62:207e27. https://doi.org/10.1016/j.phrs.2010.04.001.

[36] Choi YH, Chin YW, Kim YG. Herb-drug interactions: focus on metabolic enzymes and transporters. Archives of

Pharmacal Research 2011;34:1843e63. https://doi.org/10.1007/s12272-011-1106-z.

[37] Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two ﬂavonolignans from milk thistle (Silybum marianum) inhibit

CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. Journal of Pharmacology and

Experimental Therapeutics 2010;332:1081e7. https://doi.org/10.1124/jpet.109.161927.

[38] Fessler MB, Rudel LL, Brown M, Sheean. Clinical assessment of CYP2D6-mediated herb-drug interactions in

humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Bone

2008;23:1e7. https://doi.org/10.1002/mnfr.200600300.Clinical.

[39] Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (Silybum marianum)

for interference with human liver cytochrome-P450 activities. Toxicology in Vitro 2011;25:21e7. https://

doi.org/10.1016/j.tiv.2010.09.001.

[40] Surana AR, Agrawal SP, Kumbhare MR, Gaikwad SB. Current perspectives in herbal and conventional drug in-

teractions based on clinical manifestations. Future Journal of Pharmaceutical Sciences 2021;7. https://doi.org/

10.1186/s43094-021-00256-w.

[41] Sørensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their

medical implications. Journal of Alternative & Complementary Medicine 2002;8:293e308. https://doi.org/

10.1089/10755530260127989.

[42] Huang CF, Lin SS, Liao PH, Young SC, Yang CC. The immunopharmaceutical effects and mechanisms of herb

medicine. Cellular and Molecular Immunology 2008;5:23e31. https://doi.org/10.1038/cmi.2008.3.

[43] Miller LG. Herbal medicinals. Archives of Internal Medicine 1998;158:2200. https://doi.org/10.1001/

archinte.158.20.2200.

[44] Kansara MB, Jani AJ. Possible interactions between garlic and conventional drugs: a review. Pharmaceutical and

Biological Evaluations 2017;4:73. https://doi.org/10.26510/2394-0859.pbe.2017.12

[45] Yang L, Li CL, Tsai TH. Preclinical herb-drug pharmacokinetic interaction of panax ginseng extract and selegi-

line in freely moving rats. ACS Omega 2020;5:4682e8. https://doi.org/10.1021/acsomega.0c00123.

[46] Jeon JH, Lee S, Lee W, Jin S, Kwon M, Shin CH, et al. Herbedrug interaction of red ginseng extract and ginseno-

side RC with valsartan in rats. Molecules 2020;25:1e19. https://doi.org/10.3390/molecules25030622.

[47] Choi MK, Song IS. Interactions of ginseng with therapeutic drugs. Archives of Pharmacal Research

2019;42:862e78. https://doi.org/10.1007/s12272-019-01184-3.

[48] Qi L-W, Wang C-Z, Du G-J, Zhang Z-Y, Calway T, Yuan C-S. Metabolism of ginseng and its interactions with

drugs. Current Drug Metabolism 2012;12:818e22. https://doi.org/10.2174/138920011797470128.

[49] Wang X, Zhang H, Chen L, Shan L, Fan G, Gao X. Liquorice, a unique “guide drug” of traditional Chinese med-

icine: a review of its role in drug interactions. Journal of Ethnopharmacology 2013;150:781e90. https://doi.org/

10.1016/j.jep.2013.09.055.

[50] Borrelli F, Izzo AA. Herb-drug interactions with St John’s Wort (hypericum perforatum): an update on clinical

observations. The AAPS Journal 2009;11:710e27. https://doi.org/10.1208/s12248-009-9146-8.

[51] Williamson EM. Drug interactions between herbal and prescription medicines. Drug Safety 2003;26:1075e92.

https://doi.org/10.2165/00002018-200326150-00002.

References 263

https://t.me/med1917

[52] Okonta J, Uboh M, Obonga W. Herb-drug interaction: a case study of effect of ginger on the pharmacokinetic of

metronidazole in rabbit. Indian Journal of Pharmaceutical Sciences 2008;70:230e2. https://doi.org/10.4103/

0250-474X.41462.

[53] Paramdeep G. Efﬁcacy and tolerability of ginger (Zingiber Ofﬁcinale) in patients of osteoarthritis of knee. Indian

Journal of Physiology & Pharmacology 2013;57:177e83.

[54] Zhang F, Huang J, He RJ, Wang L, Huo PC, Guan XQ, et al. Herb-drug interaction between Styrax and warfarin:

molecular basis and mechanism. Phytomedicine 2020;77:153287. https://doi.org/10.1016/j.phymed.2020.

153287.

[55] Ma L, Zhao L, Hu H, Qin Y, Bian Y, Jiang H, et al. Interaction of ﬁve anthraquinones from rhubarb with human

organic anion transporter 1 (SLC22A6) and 3 (SLC22A8) and drug-drug interaction in rats. Journal of Ethno-

pharmacology 2014;153:864e71. https://doi.org/10.1016/j.jep.2014.03.055.

[56] Shia CS, Juang SH, Tsai SY, Lee Chao PD, Hou YC. Interaction of Rhubarb and methotrexate in rats: in vivo and

Ex vivo approaches. American Journal of Chinese Medicine 2013;41:1427e38. https://doi.org/10.1142/

S0192415X1350095X.

[57] Wanwimolruk S, Phopin K, Prachayasittikul V. Cytochrome P450 enzyme mediated herbal drug interactions

(Part 2). EXCLI Journal 2014;13:869e96.

[58] Chen A, Qin X, Tang Y, Liu M, Wang X. Evaluation of enzyme inhibition kinetics in drug-drug interactions.

Chemico-Biological Interactions 2014;222:133e4. https://doi.org/10.1016/j.cbi.2014.10.010.

[59] Nayeri A, Wu S, Adams E, Tanner C, Meshman J, Saini I, et al. Acute calcineurin inhibitor nephrotoxicity sec-

ondary to turmeric intake: a case report. Transplantation Proceedings 2017;49:198e200. https://doi.org/

10.1016/j.transproceed.2016.11.029.

[60] Lim JW, Chee SX, Wong WJ, He QL, Lau TC. Traditional Chinese medicine: herb-drug interactions with aspirin.

Singapore Medical Journal 2018;59:230e9. https://doi.org/10.11622/smedj.2018051.

[61] Hu S, Belcaro G, Dugall M, Peterzan P, Hosoi M, Ledda A, et al. Interaction study between antiplatelet agents,

anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (MerivaÒ). European

Review for Medical and Pharmacological Sciences 2018;22:5042e6. https://doi.org/10.26355/

EURREV_201808_15647.

[62] Rodda HC, Molmoori RK, Samala S, Banala N, Ciddi V. An insight into herb - drug interactions. International

Journal of Pharmaceutical Sciences and Nanotechnology 1970;2:689e706. https://doi.org/10.37285/

ijpsn.2009.2.4.3.

[63] Cohen PA, Ernst E. Safety of herbal supplements: a guide for cardiologists. Cardiovascular Therapeutics

2010;28:246e53. https://doi.org/10.1111/j.1755-5922.2010.00193.x.

[64] Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic

drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetology & Metabolic Syn-

drome 2017;9:1e12. https://doi.org/10.1186/s13098-017-0254-9.

[65] Thikekar AK, Thomas AB, Chitlange SS. Herb-drug interactions in diabetes mellitus: a review based on pre-

clinical and clinical data. Phytotherapy Research 2021;35:4763e81. https://doi.org/10.1002/ptr.7108.

[66] Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interac-

tions: a systematic review by the natural standard research collaboration. Current Drug Metabolism

2008;9:1063

e120. https://doi.org/10.2174/138920008786927785.

[67] Holstege CP, Mitchell K, Barlotta K, Furbee RB. Toxicity and drug interactions associated with herbal products:

ephedra and St. John’s Wort. Medical Clinics of North America 2005;89:1225e57. https://doi.org/10.1016/

j.mcna.2005.08.002.

10. Herbal drug interaction and effects on phytopharmaceuticals264

https://t.me/med1917

Clinical, ethical, and regulatory

issues of botanicals

Niraj Parihar

, Kalyani Barve

and Lokesh Kumar Bhatt

Department of Pharmacology, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Vile

Parle (West), Mumbai, India;

Department of Pharmacology, SPP School of Pharmacy &

Technology Management, NMIMS University, Vile Parle (West), Mumbai, India

1. Introduction

Not onlyin developing nations, but also in rich ones, public interest in natural treatmentshas

risen substantially in recent decades. This has enhanced the possibilities for herbal medicines to

be tradedinternationally. Although herbal medicines have bee n used for centuries, the chronol-

ogy of herbal medicine regulation differs by jurisdiction, with some countries having regulated

them for a long period and others only lately. It is due to fact that therapies employing these

compounds have shown promising results, and the efﬁcacy of numerous herbal medications

has been established, many of them remain untested, and their usage is either poorly controlled

or not checked at all. As a result, there is insufﬁcient understanding of their method of action,

contraindications, and interactions with existing orthodox medications and functional foods to

promote that these agents are safe to use [1]. Plant-based herbal therapy, also known as botan-

ical medicine or phytomedicine, has long been utilized in primary care in many nations across

the world, with over 70,000 species of plants presently employed for therapeutic purposes [2].

Herbal remedies are plant-derived materials or products with medicinal or other human health

advantages that contain either raw or processed components from one or more plants. Without

sufﬁcient knowledge of thesebotanicals or context about “healthclaims,” itis possible that these

goods will be mistakenly substituted for pharmaceuticals, posing a risk to the customer. This

review summa rizes various issues faced by botanicals (Fig. 11.1).

The quality of the raw materials, whi ch can include hundreds of natural constituents, and

processes adopted during manufacture determine the safety, effectiveness, and quality of

ﬁnished herbal medicine products. The common perception of herbal medicine is that it is

CHAPTER

265

Phytopharmaceuticals and Herbal Drugs

https://t.me/med1917

safe since it is herbal (natural) or traditional (or carries no risk for harm). Herbal medicines

and associated practices have been scientiﬁcally established to create adverse effects if the

product or therapy is of low quality , or if it is used incorrectly or in combination with other

medications. The absence of modern scientiﬁc proof for clinical efﬁcacy and mechanisms of

action may prevent those herbal crude extracts/fractions from being acknowledged as “herb-

al drugs” outside of their culture of origin. Clinical issues are one of the most difﬁcult respon-

sibilities in trials examining crude extracts/fractions from herbal materials (referred to as

herbal drug trials), and many researchers may lack conﬁdence in dealing with such issues

[3]. Ethics committees have also had difﬁculty justifying the conduct of such experiments

ethically, which may complicate the ethical approval procedure. To aid both clinical investi-

gators and ethics committee members in dealing with ethical difﬁculties in herbal drug trials,

a consolidated framework for ethical considerations expressly relevant to herbal drug studies

is desperately needed [4]. Herbal medications are also gaining popularity in indu strialized

countries such as the United States, Europe, and elsewhere, thanks to a variety of comple-

mentary and alternative medicine (CAM) approaches. Herbal medicines bring in a lot of

money around the world, which has le d to the entry of counterfeit, low-quality, or contam-

inated herbal goods into international markets, posing severe patient safety concerns. Due to

the complexity of herbal medications, testing for safety, effectiveness, and quality is limited.

Herbal drugs are not regulated as strictly as allopathic medicines in developing countries,

where they are used by over 80% of the population, whereas in deve loped countries, where

they are used less, herbal drugs are manufactured and used in accordance with good

manufacturing practice (GMP) and good clinical practice (GCP). Herbal drugs’ widespread

use does not imply that they are safe or effective.

FIGURE 11.1 A summary of issues of botanicals and their probable solutions.

11. Clinical, ethical, and regulatory issues of botanicals266

https://t.me/med1917

2. Need for regulation of botanicals

The global herbal supplements market is inclining, thanks to rising demand for natural

products and increased awareness of preventive healthcare, which has resulted in increased

spending on health and wellness [5]. Herbal products have become a major component of

public healthcare all around the world. Various surveys performed for traditional medicine

have featured their widespread use. Despite their large market potential, developing nations’

contributions to the global herbal industry are limited due to a lack of quality control, stan-

dardization processes for evaluating traditional medicines to assure safety, efﬁcacy, qual ity

control, registration procedures, and other factors. The majority of herbal formulations are

polyherbal, making them even more challenging to identify bioactive and marker chemicals.

The polyherbal formulation has a greater and longer therapeutic potential than a single herb.

In general, herbal remedies’ efﬁcacy is the consequence of the coordinated activity of multiple

active chemicals as well as accompanying inert substances in treating a certain condition.

Traditional remedies are unable to enter the market as a drug product in developed countries

due to a lack of studies on active ingredient identiﬁcation, as well as safety and efﬁcacy ev-

idence. The generation of data on safety is more important than assessing the efﬁcacy of herb-

al medicine, and this necessitates the conduct of a clinical study on a large number of people.

Clinical trials of herbal products are advised to broaden their acceptance and the use of

consistent batches is encouraged. Healthcare professionals (HCPs) ﬁnd it difﬁcult to accept

the use of herbal formulations as they lack the knowledge for it [6,7]. Many botanicals fail

or meet little success in phase 3 clinical trials; hence, HCPs seldom recommend these botan-

icals. Plant extracts are studied highly in clinical trials where they fail to show positive results,

after performing excellently in preclinical studies. The production of scientiﬁc evidencee

based pharmacological and clinical data for herbal medicinal items can aid in the integration

of herbal medicinal items into mainstream medical procedures. Traditional medicine formu-

lations can achieve global regulatory acceptability when bioactive or marker phytochemicals

are de ﬁned and quantiﬁed.

3. Clinical issues of botanicals

Herbal drug research is fraught with difﬁ culties that must be overcome. These concerns

include ﬁnancial, ethical product standardization, study design, and regulatory requirements

before ﬁling an investigational new drug (IND) to perform big phase 3 trials. The inclusion

criteria should be based on either contemporary medicine or herbal medicine diagnosis, ac-

cording to the authors. In herbal and contemporary medicine approaches, the interpretation

of the condition and, as a result, the disease criteria can differ. As a result, deﬁning inclusion

and exclusion criteria and thus generating a homogeneous group of individuals based on

herbal medicine diagnosis becomes challenging. The selection of controls is another problem

in (randomized control trials) RCTs of herbal medications [8]. Controls are chosen to be as

similar to the intervention group as possible, as comparator comparability is required if

the study is to give evidence of a speciﬁc impact of the herbal medicine [9]. Color, odor, dura-

tion, frequency of intake, and patient trust, and physical circumstances in which treatments

3. Clinical issues of botanicals 267

https://t.me/med1917

<<< < Предыдущая 17 18 19 20 21 22 23 24 25 26 27 2829 / 4929 30 31 32 33 34 35 36 37 38 39 40 41 > Следующая >>>

Соседние файлы в папке Библиотека им академика М.И. Перельмана

#
10.10.20268 Мб0Книга_5693_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20268 Мб0Книга_5694_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20268 Мб0Книга_5695_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20267 Мб0Книга_5696_Библиотеки_им_академика_М_И_Перельмана.pdf
#
10.10.20267 Мб0Книга_5697_Библиотеки_им_академика_М_И_Перельмана.pdf
#
12.10.20267 Мб0Книга_5698_Библиотеки_им_академика_М_И_Перельмана.pdf
#
12.10.20267 Мб0Книга_5699_Библиотеки_им_академика_М_И_Перельмана.pdf
#
12.10.20266 Мб0Книга_57_библиотеки_им_акад_М_И_Перельмана.pdf
#
30.08.202678 Мб0Книга_570_Библиотеки_им_академика_М_И_Перельмана.pdf
#
12.10.20267 Мб0Книга_5700_Библиотеки_им_академика_М_И_Перельмана.pdf
#
12.10.20267 Мб0Книга_5701_Библиотеки_им_академика_М_И_Перельмана.pdf